Fin Cascade
Get Android appGet iOS app

Prices as of 9 Oct 2026 close · Not investment advice

HALEOS LABS LIMITED

NSE: HALEOSLABSPharmaceuticals

Share price

₹1,563.70

-0.26% close of 9 Oct 2026

Market cap ₹469 CrP/E 29.7

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 8 Oct 2026, the close above is 9 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

47

out of 100 · worked out 9 Oct 2026

How the business score works

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹469 Cr

P/E ratio

29.7

P/B ratio

2.2

ROCE

9.9%

ROE

8.4%

Dividend yield

0.1%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 9 Oct 2026 close52-week high ₹1,690.1052-week low ₹1,118.90

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales fell 3.1% over the past year. Meanwhile what it keeps of every 100 rupees of sales improved from 9.4% to 12.4% over the last four years.

Whether it grew faster than its sector

It grew 4.0% a year against a sector median of 13.1% — 9.1 percentage points slower.

Room to re-rate, or risk of de-rating

At 29.7× earnings against a market that pays 24.1× across 2199 companies we can price. Its own industry sits at 40.8×, across 5 companies. It is against its own five-year median of 17.4×, the 93rd percentile of its own range.

Whether growth justifies the valuation

Priced at 1.5 times its growth rate, on earnings growth of 20%.

Profit growthPrice per ₹1 profitPer 1% growth
HALEOS LABS LIMITED — this one20%/yr29.7×₹1.5
GlaxoSmithKline Pharmaceuticals Limited18%/yr40.8×₹2.3
Ajanta Pharma Limited24%/yr37.6×₹1.6
Emcure Pharmaceuticals Limited21%/yr33.9×₹1.6
Wockhardt Limited43%/yr81.1×₹1.9
Sai Life Sciences Limited227%/yr84.9×—

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 87 of 130 on returns, 107 of 127 on growth, 86 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

No durable advantage shows in the numbers: it earns 9.9% on capital, ahead of 33% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

No — Over the last five years it made ₹99 crore of cash from the business but spent ₹178 crore on plant and equipment, ₹79 crore more than it made; the gap was mostly borrowed — borrowings rose from ₹80 crore to ₹111 crore. And the profit is real: of every 100 rupees it reported over 8 years, about 148 arrived as cash (before interest, which is why it can exceed the profit). Its cash comes back faster than it used to: it went from being waiting 17 days for its cash to waiting 5 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

8 of 10 checks clear · 80%

How the profit check works

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Announced 5 Aug 2026 · Consolidated · Unaudited

Revenue

₹73 Cr

Revenue vs last year

-11.6%

Revenue vs last quarter

-2.9%

Net profit

₹2 Cr

Profit vs last year

-58.1%

Profit vs last quarter

+425.8%

Net margin

2.5%

EPS

₹8.75

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹469 Cr
Prev close
₹1,563.70
52w High
₹1,774
52w Low
₹1,091
Enterprise value
₹578 Cr
Beta
0.7
Price CAGR 1y
40.0%
Price CAGR 3y
46.0%
Price CAGR 5y
15.0%
Price CAGR 10y
—

Ratios

Return on assets
4.0%
PEG ratio
1.5
P/E ratio
29.7
P/B ratio
2.2
EV / EBITDA
14.1
Industry P/E
37.6
ROCE
9.9%
ROCE 5y average
9.8%
ROE
8.4%
Debt / Equity
0.5
Interest coverage
4.6
Dividend yield
0.1%
ROE 3y average
8.0%
ROE last year
8.0%

Annual P&L

Annual revenue
₹334 Cr
Annual profit
₹18 Cr
Operating margin
13.0%
Net profit margin
5.4%
EBITDA margin
13.5%
Sales growth 3y
1.9%
Sales growth 5y
4.7%
Profit growth 3y
20.0%
Profit growth 5y
5.0%
EPS
₹57.3
Sales growth TTM
-3.0%
Profit growth TTM
-8.0%
Dividend payout
3.0%

Quarter P&L

Sales latest quarter
₹73 Cr
Profit latest quarter
₹2 Cr
YoY quarterly sales growth
-11.6%
YoY quarterly profit growth
-58.1%
OPM latest quarter
12.5%

Balance Sheet

Book Value
₹713
Face Value
₹10.0
Total debt
₹111 Cr
Total cash
₹2 Cr
Borrowings
₹111 Cr
Reserves / Equity
70.3

Cash Flow

Operating cash flow
₹37 Cr
Free cash flow
-₹21 Cr
FCF yield
-6.0%
Net cash flow
₹1 Cr

Shareholding

Promoter holding
72.1%
FII holding
0.0%
DII holding
0.3%
Public holding
27.6%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,781.0033.84,27,3220.902,901.26.015,299.910.520.5
Divi's Lab.9,588.0085.42,54,5310.31902.065.53,080.027.822.0
Torrent Pharma.4,716.2080.41,79,3890.81566.05.84,921.054.915.2
Zydus Lifesci.1,153.0023.61,15,0120.09990.2-35.18,017.022.021.1
Laurus Labs2,052.80101.41,10,9150.10362.1125.52,026.329.117.8
Cipla1,327.2030.01,07,2210.98785.6-39.27,119.32.315.5
Mankind Pharma2,500.0048.41,03,2610.04574.129.64,030.612.913.5
Haleos Labs Limited1,584.7030.34790.091.8-36.372.9-11.69.9
Median417.9034.52,2080.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales75697290937885898381957573
Expenses72616379767072827168817164
Material Cost332840453640
Change in Inventories6.636.73-8.81-1.12-4.980
Purchases of Stock-in-Trade00000-14
Employee Cost161616171618
Other Expenses261921202420
Operating Profit2.547.939.3011168.57137.421214144.169.12
OPM %3.401113131811158.331417155.5413
Other Income0.610.270.582.360.442.040.062.3410.420.182.010.46
Exceptional items (within Other Income)000000
Interest2.182.812.342.842.402.142.142.031.871.621.541.421.90
Depreciation3.703.733.733.783.683.763.763.803.823.893.913.854.24
Profit before tax-2.731.663.817.10114.716.913.937.028.498.780.903.44
Tax %40127-8.148.73333030113824246247
Net Profit-3.83-0.444.126.477.103.304.863.484.396.426.650.351.84
EPS in Rs-5.952.2514202315189.821420221.468.77
Diluted EPS in Rs9.831420221.448.75

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales378261266350316306345334324
Expenses343235235316287275300289283
Material Cost150147
Change in Inventories4.15-8.18
Purchases of Stock-in-Trade00
Employee Cost6065
Other Expenses8685
Operating Profit352530352931454541
OPM %9101110910131313
Other Income2221454523
Exceptional items (within Other Income)00
Interest65567108.7176
Depreciation688101115151516
Profit before tax25152033179.85262522
Tax %3031312331362829
Net Profit18101425116.33191815
EPS in Rs593445843830675752
Diluted EPS in Rs6757
Dividend Payout %30324523

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
—
5 years
5%
3 years
2%
TTM
-3%

Compounded profit growth

10 years
—
5 years
5%
3 years
20%
TTM
-8%

Stock price CAGR

10 years
—
5 years
15%
3 years
46%
1 year
40%

Return on equity

10 years
—
5 years
8%
3 years
8%
Last year
8%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital333333.023.023
Reserves103113126149166174194211
Borrowings4765658010010186111
Other Liabilities11672108125126114107130
Minority Interest1516
Total Liabilities270253302357395391390454
Fixed Assets118124130142228223232268
CWIP316385116010
Investments00000000
Other Assets148113134164166162158176
Total Assets270253302357395391390454

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity301535-1115243437
Cash from Investing Activity-44-27-26-7-31-18-15-58
Cash from Financing Activity1512-31117-7-1921
Net Cash Flow1-06-80-1-01
Free Cash Flow6-9-0-53-28419-21

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days4030473553617367
Inventory Days116149164159184196163210
Days Payable140101163146127143129162
Cash Conversion Cycle16784848110115107116
Working Capital Days1418217241175
ROCE %121312871210

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters707171717171717171727272
FIIs0000.010.02000.030000
DIIs000000000.030.290.300.31
Public302929292929292929282828
No. of Shareholders8,4438,2338,1167,8617,8497,6267,4797,4127,5217,1256,9376,859

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +39.8% (₹1,118.90 → ₹1,563.70)Brick size ₹52.48 (fixed)Bricks 34
₹1,200₹1,400₹1,564Nov '25Jan '26Apr '26Jun '26Aug '26
Price moved up one brickPrice moved down one brickLast close ₹1,563.70 on 9 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

109inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

30.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

News

News and filings about HALEOS LABS LIMITED. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • consumable stores
  • pharmaceutical raw materials and packing materials for APIs/intermediates

Sells to

  • ChemWerth Inc. · APIs and intermediates; FY25 RPT sale of goods Rs 42.01 lakh. ChemWerth (USA) is also the…
  • SMS Pharmaceuticals Limited · APIs and intermediates; FY25 RPT sale of goods Rs 1,924.05 lakh (purchases from them only…
  • Sun Pharmaceutical · APIs and intermediates
  • Viatris (formerly Mylan) · APIs and intermediates for regulated markets
  • Zydus Lifesciences · APIs and intermediates

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE320X01016

Plants

  • In-house R&D Centre, Sanathnagar
  • Mahi Drugs API Facility, Visakhapatnam
  • Unit 1 - Kazipally API Facility
  • Unit 4 - IDA Jeedimetla Warehouse

News impact

Big market events that reach HALEOS LABS LIMITED, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

23 Sep 2026unspecified₹1.5
24 Sep 2025unspecified₹1.5
23 Sep 2024unspecified₹1.5
22 Sep 2023unspecified₹1.5
22 Sep 2022unspecified₹1.5
20 Sep 2021unspecified₹1.5
19 Sep 2019unspecified₹1.5

Splits, bonuses & buybacks

  • daily-prices repair: 1 rows from NSE's archive (replace 0, delete 0, insert 1), 2026-02-01..2026-02-01 (docs/flat_day_repair.md)1× · 1 Feb 2026
  • nse-rename-history fill: 2044 NSE bars before cutoff, ISIN INE320X01016@2017-08-17, symbols SMSLIFE (docs/nse_rename_history.md)1× · 17 Nov 2025

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.